Maurice was discovered this morning attempting to construct a scale model of cellular mitochondria using banana peels, muttering something about how Rocket Pharmaceuticals just got FDA approval but the stock went down anyway—clearly, the market needed a lesson in reading its own press releases.
Listen, I’ve been throwing fruit at financial charts for a long time, and I’ve seen some confusing market reactions. But watching Rocket Pharmaceuticals (RCKT) get FDA accelerated approval for KRESLADI—a gene therapy for severe Leukocyte Adhesion Deficiency-I in children—and then watch the stock drop 8.9% is like ordering a premium banana split, getting it delivered, and then complaining about the ice cream. Something is deeply wrong with the narrative we’re being sold.
Let me back up. Rocket Pharmaceuticals is a late-stage biotech company focused on something genuinely exciting: gene therapies for rare, devastating diseases. We’re talking about disorders where current treatment options are basically “I’m sorry, your condition is genetic and incurable.” These aren’t blockbuster drugs for millions of people. These are therapies that can fundamentally alter lives—and the lives of small patient populations willing to pay for that miracle.
And here’s the thing: Rocket just proved their science works. KRESLADI is now approved. That’s not a “maybe.” That’s not a “clinical trial pending.” That’s an FDA stamp that says “yes, this works, and we’re letting you sell it.” The accelerated approval pathway exists specifically because the FDA looked at the data and said, “This is solving a real problem that patients desperately need solved.”
So why did the stock crater?
Market psychology, my friends. And this is exactly where patient capital—the kind of capital that understands biotech volatility—makes its money. The knee-jerk reaction to KRESLADI’s approval was essentially: “Wait, but this is a small patient population. How big is the market really?” Fair question. But also: completely missing the forest for the banana peel.
The Pipeline is Deeper Than You Think
Here’s what gets buried in the headlines: KRESLADI is Rocket’s first FDA approval, but it’s not their only program. The company is running what I’d call a “carefully engineered orchard” of gene therapy candidates. They’ve got in vivo AAV programs targeting cardiac diseases (Danon disease, Arrhythmogenic Cardiomyopathy, Dilated Cardiomyopathy) and ex vivo lentiviral programs for blood disorders (Fanconi Anemia, Pyruvate Kinase Deficiency).
Let me translate what that means: Rocket isn’t betting everything on one banana. They’ve got multiple shots on goal in therapeutic areas where patients literally have no alternatives. Some of these programs are in Phase 2. Others are still in Phase 1. But the fact that the company got KRESLADI across the finish line proves their platform works. That de-risks the entire pipeline.
Think of it this way: Would you rather own a company with one approved drug and a bunch of speculative programs, or a company that just proved their scientific approach actually works and has that proven approach being applied across six different disease areas? Because that’s what happened here. The stock market sold the approval and bought the fear.
The Valuation Math is Broken (In Rocket’s Favor)
Here’s where my tail started twitching. Rocket is trading at $3.585, near its 20-day moving average of $4.02. The 52-week range? $2.19 to $8.26. That $8.26 was reached before the FDA approval. This company is literally cheaper now than it was before good news. The market is pricing in maximum skepticism about the commercial opportunity.
The debt-to-equity ratio sits at 8.97—yes, that’s high—but in biotech, you need to look at it through the lens of what comes next. With FDA approval in hand and a pipeline that just got significantly de-risked, Rocket’s ability to raise capital or negotiate partnerships just improved substantially. That leverage, which looked scary three months ago, now looks like a problem with a solution.
And here’s the thing nobody mentions: the short ratio is 4.64%. That’s a meaningful short position in a stock that just de-risked itself dramatically. Shorts are usually right about biotech failures. But when a biotech succeeds? That’s when shorts become the most predictable profit opportunity in the market. They have to cover, and they don’t want to hold the bag.
The analysts agree, by the way. Eleven analysts are covering this stock with a consensus target of $8.48. That’s a 136% upside from current prices. Foxy’s more conservative target of $6.50 gives you 81% upside. For a medium-risk biotech with FDA approval, de-risked pipeline, and serious short covering to come? That’s not ambitious. That’s conservative.
Why the Market Got This Wrong (For Now)
Here’s my theory, and I’m going to throw a banana at the whiteboard to illustrate it: The market is suffering from rare disease myopia. When a company gets approval for a therapy that treats a patient population measured in hundreds or maybe a few thousand, Wall Street default mode is to assume the commercial opportunity is proportionally small. But these aren’t typical pharmaceuticals competing on price in a crowded market. These are gene therapies for genetic disorders with no current treatment.
For severe LAD-I? There might be 300-500 eligible patients in the US. But what do you charge for a gene therapy that cures a genetic disease? You don’t charge for a course of treatment. You charge for a cure. And families with a dying child? Their willingness to pay is infinite. Payers understand this because they understand the alternative is early death. The economic math for rare disease gene therapies is completely different from traditional pharma.
Plus—and this matters—the FDA approval for KRESLADI opens the door to significant reimbursement discussions in 2025-26. That’s happening right now. That’s not speculation. The approval happened in March 2026. Payer negotiations for breakthrough therapies move faster than traditional drugs because there’s no alternative. You either pay for KRESLADI, or your patient dies of a genetic disease you can’t treat any other way.
The market priced in maximum cynicism about commercial potential and completely missed the reimbursement landscape shift that’s happening in real time.
The Risk That Keeps Me Honest
I’m a monkey, but I’m not a delusional monkey. There are real risks here. Free cash flow is deeply negative at -$104.8 million. The company is burning cash because that’s what biotech companies do—they invest in R&D and clinical trials before they have revenue. But with FDA approval and cash from KRESLADI sales beginning to flow, that trajectory is about to change. The approval is the inflection point.
Also: rare disease means small patient populations. If you’re betting on a 10-bagger, you’re probably not getting it. But if you’re betting on 80% upside from undervaluation plus de-risking? That’s very achievable. The company doesn’t need to be a huge pharma success to deliver strong returns. It just needs to execute on commercialization and advance its pipeline. Both are now significantly more likely than they were two weeks ago.
The beta of 0.574 is actually your friend here. This stock moves less violently than the market, which means you’re getting optionality (the pipeline programs) without the volatility. That’s the definition of a mispriced asymmetric opportunity.
Where This Lands
Rocket Pharmaceuticals just proved that its gene therapy platform works. The market responded by getting scared of the small patient populations and completely ignored the reimbursement tailwinds, the de-risked pipeline, and the short covering that’s probably coming. This is what happens when you combine information asymmetry (most people don’t understand rare disease economics) with institutional fear (biotech is scary) and short positioning (shorts need the stock to fail to make their thesis work).
Three years from now, I expect Rocket to have multiple approved therapies, significant revenue, and a much clearer path to profitability. The stock at $3.58 is essentially pricing in all the downside scenarios and none of the upside scenarios. That’s not analysis. That’s panic.
This is exactly the kind of opportunity that makes me adjust my tiny tie and get serious: You’ve got FDA approval de-risking the entire platform, a pipeline full of shots on goal, analyst consensus at $8.48, shorts ready to cover, and a stock that just got crushed on good news. The market occasionally just gives you what you want if you’re willing to wait for it to stop overreacting.
I’m buying at $3.48. Foxy’s target of $6.50 is how you know this is undervalued—even the conservative analysis assumes 87% upside. Sometimes the market gets it wrong. This looks like one of those times.
Trained Market Monkey 